Canntab Therapeutics Limited

Canntab Therapeutics — Investor Presentation (December 2020)

15 slides from Canntab Therapeutics's investor presentation, December 2020

  1. Slide 1: Corporate Presentation

    CORPORATE PRESENTATION CSE: PILL | OTCQB: CTABF | FSE:TBF1 CSE: PILL | OTCQB: CTABF | FSE:TBF1 December 2020 Canntab Therapeutics Limited © 2020

  2. Slide 2: Disclaimer

    DISCLAIMER This presentation contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", or "does not expect", "is expected", "b

  3. Slide 3: What We Do

    WHAT WE DO Canntab Therapeutics is the industry leader in solid oral dose formulations of cannabis with a product line of cannabinoid (THC & CBD) and terpenoid blends in exacting dosages. With one US Patent granted on September 17th of this year, and 8 more patents pending in Canada and the United S

  4. Slide 4: What's Happening Now

    WHAT’S HAPPENING NOW  We received our Cannabis Licence, (Processing - Standard, Federal Sales - Medical).  We cleared the 60 days notice period after submitting our Notice of New Cannabis Product.  Full scale hard pill manufacturing has begun at our facility in Markham, Ontario.  We received a U

  5. Slide 5: Strong IP Portfolio

    STRONG IP PORTFOLIO 1 US patent granted, with 8 more patents pending in the United States and Canada covering our proprietary processes and hard pill formulations for,  Extended Release  Sustained Release  Instant Release In August 2019, the Geneva-based International Preliminary Report on Patent

  6. Slide 6: Proprietary Process

    PROPRIETARY PROCESS Our patent pending proprietary processes allows us to create hard pill formulations that starts with cannabis oil in water emulsions, a unique process in the industry to date. Oil emulsion >> wet granulation >> dried granulation >> blending >> tablet pressing >> coating OUR INNOV

  7. Slide 7: Meeting Medical Standards

    MEETING MEDICAL STANDARDS Current delivery mechanisms such as smoking or vaping cannabis, consuming edibles, gel caps, oils and tincture (droppers) do not provide the medical community, including Doctors, patients or the average consumer, with an attractive and professional cannabis solution. CANNTA

  8. Slide 8: Therapeutic Window

    THERAPEUTIC WINDOW Smoking cannabis can result in a large initial dose of the drug followed by a precipitous drop. Edibles dosing is unpredictable, making it difficult to maintain therapeutic relief. Our solution, an extended release (XR) tablets with flash melt technology, quickly brings the patien

  9. Slide 9: How We Generate Revenue

    HOW WE GENERATE REVENUE HARD PILL LICENSING PRODUCT SALES Q4 2020 ONLINE STORE MANUFACTURING SALES PROFIT Q4 2020 Q1 2021 Canntab Therapeutics Limited © 2020 9

  10. Slide 10: Approaching the Opioid Crisis

    APPROACHING THE OPIOID CRISIS The opioid crisis claimed 4,588 Canadians in 2018. That’s approximately 1 life lost every 2 hours1. Almost 2 million people filled over 9 million prescriptions for opioids in Ontario, in 2015/20162. Canntab will conduct a clinical study in 2021 with leading orthopedic s

  11. Slide 11: Tablet Economics

    TABLET ECONOMICS Note: Sensitivity Analysis is meant to be illustrative and is not intended to used as a forecast. Canntab Therapeutics Limited © 2020 11

  12. Slide 12: Capitalization

    CAPITALIZATION MAINTAINING ZERO DEBT AND ONLY 30 DAYS OF TRADE PAYABLES Canntab Therapeutics Limited © 2020 12

  13. Slide 13: Looking at the Future

    LOOKING AT THE FUTURE  Clinical trial with Dr. Garbuz at UBC to investigate potentially opioid sparing CBD/THC formulations in 2021, as we work towards acquiring Drug Identification Numbers (DINs).  Q1 2021 release of our new online platform and online store, to include a telehealth department tha

  14. Slide 14: Management Team

    MANAGEMENT TEAM Jeff Renwick, Co-Founder Richard Goldstein, Co-Founder President & Head of Production Chief Financial Officer  Former President/CEO of Orbus Pharma  Founder First Republic Capital, Co-Founder Fraser McKenzie, former EVP/Head of IB at Standard  Business Development for Indukern Che

  15. Slide 15: Contact Us

    CONTACT US Richard Goldstein Co-founder & Chief Financial Officer (647) 209-3279 Richard@Canntab.ca Larry Latowsky Chief Executive Officer (416) 458-6491 Larry@Canntab.ca Canntab Therapeutics Limited © 2020 15

Canntab Therapeutics — Investor Presentation (December 2020) on 6ix